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The influence of human genetic 
variation on Epstein–Barr virus 
sequence diversity
Sina Rüeger1,2,39, Christian Hammer3,39, Alexis Loetscher2,4,39, Paul J. McLaren5,6, 
Dylan Lawless1,2, Olivier Naret1,2, Daniel P. Depledge7, Sofia Morfopoulou7, Judith Breuer7, 
Evgeny Zdobnov2,4, Jacques Fellay1,2,8* & the Swiss HIV Cohort Study*
Epstein–Barr virus (EBV) is one of the most common viruses latently infecting humans. Little is 
known about the impact of human genetic variation on the large inter-individual differences observed 
in response to EBV infection. To search for a potential imprint of host genomic variation on the 
EBV sequence, we jointly analyzed paired viral and human genomic data from 268 HIV-coinfected 
individuals with CD4 + T cell count < 200/mm3 and elevated EBV viremia. We hypothesized that the 
reactivated virus circulating in these patients could carry sequence variants acquired during primary 
EBV infection, thereby providing a snapshot of early adaptation to the pressure exerted on EBV by 
the individual immune response. We searched for associations between host and pathogen genetic 
variants, taking into account human and EBV population structure. Our analyses revealed significant 
associations between human and EBV sequence variation. Three polymorphic regions in the human 
genome were found to be associated with EBV variation: one at the amino acid level (BRLF1:p.
Lys316Glu); and two at the gene level (burden testing of rare variants in BALF5 and BBRF1). Our 
findings confirm that jointly analyzing host and pathogen genomes can identify sites of genomic 
interactions, which could help dissect pathogenic mechanisms and suggest new therapeutic avenues.
Human genetic variation plays a key role in determining individual responses after exposure to infectious agents. 
Even though susceptibility or resistance to a microbial challenge is the final result of dynamic interactions 
between host, pathogen and environment, human genetic polymorphisms have been shown to have an important, 
directly quantifiable impact on the outcome of various  infections1,2.
Genome-wide association studies (GWAS) have proven powerful to identify genetic regions implicated in a 
wide range of complex traits in both health and  disease3. In the field of infectious diseases, several clinical and 
laboratory phenotypes have been investigated, including, for example disease  susceptibility4,5, clinical  outcomes6, 
adaptive  immunity7–9 or drug  response10. In chronically infected patients, however, the pathogen genome itself 
provides a promising complementary target to investigate the impact of host genomic diversity on infection. 
While one part of the variation observed in pathogen DNA or RNA sequence is present at the transmission event, 
another fraction is acquired during the course of an infection, resulting at least partially from selective pressure 
exerted by the host response on the infectious agent. The phenomenon of within-host evolution has been exten-
sively investigated for both  viruses11–13 and  bacteria11,14. Pathogen genomic variation can thus be considered an 
intermediate phenotype that is detectable as a footprint of within-host evolution. This can serve as a basis for a 
joint association analyses of host and pathogen genome variation, which we called genome-to-genome (G2G) 
 analysis15, a more powerful approach than using a clinical outcome alone. A global description of the adaptive 
forces acting on a pathogen genome during natural infection holds the potential to identify novel therapeutic 
and diagnostic targets and could inform vaccine design  efforts16.
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A G2G analysis for the quickly evolving human immunodeficiency virus (HIV) identified strong associations 
of single nucleotide polymorphisms (SNPs) in the HLA class I region with multiple amino acid variants across 
the viral  genome15. More recent work showed an impact of variation in the HLA class II and interferon lambda 
4 (IFNL4) loci on hepatitis C virus (HCV) sequence  diversity17–19. While the rate of evolutionary change in RNA 
viruses is higher than in DNA  viruses20, the latter also present considerable amounts of inter- and intra-host 
variation. Among herpesviruses, it has been shown that human cytomegalovirus (HCMV) has higher genomic 
variability than other DNA  viruses21. Recent genome sequencing efforts demonstrated that the same holds true 
for Epstein–Barr virus (EBV)22,23.
EBV is a widespread human pathogen that causes infectious mononucleosis in about 10% of individuals dur-
ing primary infection. EBV infection occurs most often early in life, with about 30% of children being seropositive 
by age 5, 50% by age 10 and up to 80% by age  1824. This human infecting herpesvirus has also been associated 
with post-transplant lymphoproliferative  disease25 and could play a role in some autoimmune  diseases26–29. In 
addition, EBV has oncogenic properties and is implicated in the pathogenesis of multiple cancer types, predomi-
nantly Burkitt’s lymphoma, Hodgkin’s and non-Hodgkin’s lymphoma, nasopharyngeal carcinoma and gastric 
 carcinoma30,31. More than 5% of the 2 million infection-associated new cancer cases in 2008 could be attributed 
to  EBV32; it was also estimated to have caused 1.8% of cancer deaths in 2010, i.e. more than 140,000  cases33.
The EBV genome is approximately 170 Kbp long and encodes at least 80 proteins, not all of which have been 
definitively identified or characterized. After primary infection, the EBV genome persists in B cells as multicopy 
episomes that replicate once per cell cycle. In this latent mode, only a small subset of viral genes is expressed. 
Latent EBV can then reactivate to a lytic cycle, which involves higher gene expression and genome amplification 
for packaging into new infectious viral  particles34.
A small number of host and viral genomic analyses of EBV infection have been recently published, demon-
strating that human and pathogen genetic diversity plays a role in disease outcome. A study in 270 EBV isolates 
from southern China identified two non-synonymous EBV variants within the BALF2 gene that were strongly 
associated with the risk of nasopharyngeal  carcinoma35. Another group investigated the co-evolution of world-
wide EBV  strains36 and found extensive linkage disequilibrium (LD) throughout EBV genomes. Furthermore, 
they observed that genes in strong LD were enriched in immunogenic genes, suggesting adaptive immune 
selection and epistasis. In a pediatric study of 58 Endemic Burkitt lymphoma cases and 40 healthy controls, an 
EBV genome GWAS identified 6 associated variants in the genes EBNA1, EBNA2, BcLF1, and BARF137. On the 
population genetic side, a study of > 150 EBV genomes with known geographical origin revealed considerable 
variation in allele frequencies of EBV sub-populations38. Finally, the narrow-sense heritability of the humoral 
immune response against EBV was estimated to be 0.289,39.
Here, we present the first global analysis of paired human and EBV genomes. We studied full EBV genomes 
together with their respective host genomic variation in a cohort of 268 immunocompromised, HIV-coinfected 
patients. We chose untreated HIV-coinfected patients because EBV reactivation leading to viremia is more 
prevalent in immunosuppressed individuals than in an average population. Our analysis reveals three novel host 
genomic loci that are associated with variation in EBV amino acids or genes.
Materials and methods
Study participants, sample preparation. The Swiss HIV Cohort Study (SHCS) is a nationwide, pro-
spective cohort study of HIV-infected patients that enrolled > 20,000 individuals since its establishment in 1988 
and prospectively followed them at 6-month  intervals40. For this project, SHCS participants were identified 
based on written consent for human genetic testing and availability of a peripheral blood mononuclear cell 
(PBMC) sample at time of advanced immunosuppression (i.e., with CD4 + T cell count below 200/mm3) in the 
absence of antiretroviral treatment.
We obtained demographic and clinical information from the SHCS database. These included sex, age, lon-
gitudinal HIV viral load results (number of RNA copies per ml of plasma), longitudinal CD4 + T cell counts 
(number of cells per  mm3 of blood), and history of opportunistic infections.
The SHCS has been approved by the Ethics Committees of all participating institutions (Ethikkommission 
Nordwest- und Zentralschweiz, EKNZ; Kantonale Ethikkommission Bern; Ethikkommission Ostschweiz, EKOS; 
Ethikkommission Zürich; Commission cantonale d’éthique de la recherche sur l’être humain, Genève, CCER; 
Commission cantonale d’éthique de la recherche sur l’être humain, Vaud, CER-VD; Comitato etico cantonale 
Ticino). Each study participant provided written informed consent for genetic testing, and all research was 
performed in accordance with relevant guidelines and regulations.
EBV genome quantification, enrichment and sequencing. DNA was extracted from PBMCs using 
the MagNA Pure 96 DNA and the Viral NA Small Volume Kit (Roche, Basel, Switzerland). Cellular EBV load 
was then determined using quantitative real-time PCR. Samples that yielded > 100 viral copies/ul were selected 
for EBV genome sequencing.
We used the previously described enrichment procedure to increase the relative abundance of EBV compared 
to host  DNA41. Shortly, baits covering the EBV type 1 and 2 reference genomes were used to selectively capture 
viral DNA according to the SureSelect Illumina paired-end sequencing library protocol. Samples were then 
multiplexed and sequenced on an Illumina NextSeq  sequencer41.
EBV sequence analyses. We chose a reference-based approach to call variants in the pathogen data. Since 
EBNA-2 and EBNA-3s are highly variable between EBV-1 and EBV-2 strains, we suspected that reads sequenced 
from these genes would map only to their corresponding type. In an attempt to attenuate the reference-bias 
this could cause, we constructed two references, one with the whole genome of the EBV-1 strain B95-8 (acces-
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sion NC_007605) and EBNA-2 and EBNA-3s sequences from EBV-2 strain AG876 (accession NC_009334) and 
another one with the whole genome of AG876 with the EBNA-2 and EBNA-3s sequences of B95-8.
The read libraries were processed through  Trimmomatic42 to remove remnant PCR tags,  TagDust43 to elimi-
nate low complexity reads and CD-HIT44 to filter out duplicate reads. The remaining sequence reads were aligned 
to the constructs described in the previous paragraph. Following GATK best  practices45,46, we mapped the read 
libraries using BWA  mem47. We cleaned the regions around InDels using GATK v3.8’s  IndelRealigner48. As a 
last pre-processing step, we applied bwa-postalt.js, a BWA script that adjusts mapping quality score in function 
of alignments on ALT haplotypes.
Because patients can be infected by multiple EBV  strains49, we used BWA’s ALT-aware ability. In short, reads 
mapping to an ALT contig were always marked as supplementary alignment, regardless of mapping quality, unless 
they did not map to the primary assembly. This makes it easy to find unambiguously mapped reads, which we 
used as markers to quantify type 1 and type 2 EBV reads in all samples.
where #T1 and #T2 are the unambiguous read counts against type 1 and 2 haplotypes, respectively, L1 and L2 
are the length of type 1 and 2 haplotypes, respectively, and r1 and r2 are the type 1 and 2 ratios, respectively. The 
score r is the relative abundance between type 1 and type 2.
Definition of EBV amino acid variants. Since no gold standard variant set exists for EBV nor any closely 
related viral species, variant calling was performed using three different variant callers (GATK haplotypecaller, 
 SNVer50 and  VarScan251) and by selecting as bona fide variant set the intersection of the three. The identified EBV 
variants were annotated using  snpEff52. Nucleotide variants were transformed into binary amino acid matrices 
using in-house Python scripts. The whole pipeline is written in  Snakemake53 and  Python54.
This approach was benchmarked using synthetic libraries generated from B95-8 and AG876 using ART 
Illumina and RNFtools 0.3.1.355, at a range of coverage between 10 and 250X and 5 different admixture condi-
tions, 100% B95-8 or AG876, 75–25% and 50–50%. Assessing the true number of variants between EBV-1 and 
EBV-2 strains is not trivial because of the high variability in EBNA-2 and EBNA-3s regions. Therefore, we rated 
the variant callers and the consensus of the three mentioned callers on self-consistency. The performances of 
the runs were measured using the ratio of the variant counts to the size of the union of all variants called by a 
specific tested tool.
By using EBV type 2 as a reference, we focused on two types of variation in EBV strains: (1) single amino acid 
variants; and (2) burden of very rare amino acid variants (present in only 1 sample) in each viral gene (Fig. 1). 
We call these datasets EBV amino acids and EBV genes, respectively. Both datasets contain binary values, with 
a value of 1 standing for "variant present" and 0 for "no variant present". Positions with a coverage of less than 
6 × were set to “missing” and samples with more than 80% missing positions were excluded entirely. The positions 
covered by less than 6 reads were considered missing and imputed using the imputePCA function implemented 
in the missMDA R-package56. In total, we obtained 4392 amino acid variants and 83 gene variants. However, to 
limit the risk of model overfitting and because of low statistical power due to sample size we only included in 
the downstream association analyses the 575 EBV amino acids with an amino acid frequency of more than 10% 
and 52 EBV genes.
Human genotyping and imputation. A subset of 84 participants had been genotyped in the context 
of previous studies on several platforms. For the remaining 196 samples, human genomic DNA was isolated 
from PBMCs with the QIAsymphony DSP DNA Kit (Qiagen, Hilden, Germany), and genotyped using Illumina 
OmniExpress (v1.1) BeadChip arrays.
Genotype imputation was performed on the Sanger imputation server independently for all genotyping 
platforms, using  EAGLE257 for pre-phasing and  PBWT58 with the 1000 Genomes Phase 3 reference  panel59. 
Low-quality imputed variants were excluded based on imputation INFO score (< 0.8). All datasets were merged, 
only keeping markers that were genotyped or imputed for all genotyping platforms. SNPs were excluded on the 
basis of per-individual missingness (> 3%), genotype missingness (> 1%), marked deviation from Hardy–Wein-
berg equilibrium (p < 1 × 10–6) and minor allele frequency < 5% (Table 1). All quality control procedures were 
performed using PLINK 2.060.
Association analyses. We used the mixed model association implementation for binary and continuous 
outcomes in GCTA (v1.92)61,62 to search for potential associations between human SNPs and EBV variants. The 
model can be expressed with the following equation:
where the outcome y is a binary vector indicating whether an EBV variant is present (1) or not (0); X is a matrix 
that contains all covariates, ɑ represents all fixed effects of all covariates (including an intercept term), g is the 
SNP genotype vector with coded additive allele dosages 0, 1 or 2, β is the (fixed) effect of the SNP to be tested for 
association, η is the polygenic (random) effect and ε the error term. This mixed model was estimated for each 
r1 =
#T1
(#T1+ #T2) · L1
r2 =
#T2
(#T1+ #T2) · L2
r = r1− r2
yk = αX + β
(kl)gl + η + ε
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EBV variant (k) and SNP (l), and integrated over all L SNPs and K EBV variants. To estimate η, the host genetic 
relationship matrix (GRM) was calculated from QC preprocessed genotype data using GCTA 61.
The use of a mixed effects association model allows to account for population stratification of the host genome. 
To control for population stratification among EBV genomes, we included the first six principal components 
(PCs) of EBV genetic variation to the covariate matrix  X63. Other covariates were sex, age and EBV type. PCs 
Figure 1.  Illustration of EBV sequence variation. (A) The EBV genome is about 170 Kbp long and contains 83 
genes, for a total of 4392 amino acid residues. As an example, we focus on the BNRF1 gene and on two amino 
acid changes: Glu → Ala and Ser → Leu. We know for each sample the genomic variants across the whole 
genome, as illustrated with the colored nucleotides. Using the nucleotide information and a reference genome 
we can compute the amino acid changes. (B) We compare each individual (ID) to reference data and encode an 
amino acid as 1 if that individual has a non-synonymous change, and a 0 if not. This process returns us a matrix 
containing binary values, with individuals as row, and amino acids as columns. In our example, individual 2 
has an amino acid change Glu → Ala and individual 3 an amino acid change Ser → Leu. (C) To transform the 
data into outcomes for the G2G analysis we can use the amino acid matrix as it is (EBV amino acids dataset) 
or remove all amino acid columns that appear in more than 1 individual and then pool amino acids per gene 
(1 = variant present, EBV genes dataset).
Table 1.  Summary of pathogen variants, host SNPs and covariates for 268 individuals. For each covariate, we 
indicate the number of individuals measured, and distribution (mean, median, standard deviation, minimum, 
maximum for quantitative, frequency for sex). For aggregated EBV genes the frequency is shown, for host 
SNPs the MAF distribution is presented.
Dataset Variable Counts Mean Median SD Min Max
Pathogen genome (83 Rare EBV gene vari-
ation) Variant frequency 0.067 0.049 0.057 0 0.37
Pathogen genome (575 EBV amino acids) Variant frequency 0.26 0.24 0.12 0.093 0.5
Covariates Sex Male: 206, female: 62
Covariates AGE 42.02 40.79 10.98 20.25 77.52
Covariates PC1 − 8.95 − 7.12 32.53 − 69.95 76.11
Covariates PC2 7.39 8.4 30.41 − 63.83 61.8
Covariates PC3 4.45 3.19 21.41 − 46.44 51.11
Covariates PC4 − 3.91 − 6.69 20.72 − 36.49 52.11
Covariates PC5 − 5.09 − 8.39 18.76 − 51.7 56.02
Covariates PC6 − 3.16 − 3.21 18.65 − 55.69 35.68
Covariates EBV type 0.54 0.95 0.67 − 1 1
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were calculated from EBV amino acid variants using the convexLogisticPCA function from the R package 
 logisticPCA64 in  R65. As data preparation for PC computation, we removed variants with less than 5% or more 
than 95% frequency. Missing amino acid values were imputed with the imputePCA function from the R pack-
age  missMDA56.
Significance was assessed using the usual genome-wide significance threshold in European populations of 
5 × 10–8 and dividing it by the effective number of GWASs  performed66. We used  FINEMAP67 to determine the 
most likely causal SNP(s) in a 2-Mb-wide window around each significant SNP. FINEMAP requires GWAS sum-
mary statistics and LD estimations as input. To estimate LD between SNPs, we used  LDstore68. We performed 
eQTL lookups for host SNPs in  eQTLGen69,  EUGENE70 and  GTEx71.
Unless otherwise specified, all data preparation and analyses were performed using  R65.
Results
Study participants and human genetic data. PBMC samples from 778 SHCS participants were 
screened for the presence of cellular EBV DNA using RT-PCR. A total of 290 of them were identified as viremic 
for EBV (> 2000 copies). We obtained good quality human genotyping and EBV sequencing data for 268 of them, 
which were included in the association analyses. The study cohort comprised 206 male and 62 female individu-
als, between the ages of 20 and 78 (median 40) (Table 1 and Supplementary Figure S1).
We applied standard GWAS quality control (QC) procedures that yielded information for 4′291′179 SNPs 
(Table 1 and Supplementary Figure S2, which shows the distribution of the minor allele frequency spectrum 
after QC).
EBV genomic diversity and variant calling. Genome coverage was very uneven between the samples. 
Mean depth varied from less than 6 × for 14 samples, up to more than 500 × in 5 others. We also observed fluc-
tuation in coverage above 6x, which we used to exclude 12 samples in which less than 20% of the EBV genome 
was sufficiently covered (Supplementary Figure S7a). In addition, the coverage in the first sequencing batch was 
not uniform.
We estimated the clonality of EBV strain in each sample by taking advantage of the high divergence between 
EBNAs T1 and T2 haplotypes. Among the 282 sequenced samples, 57.1% were predominantly (9:1) infected 
by T1 EBV, while 5.7% were mostly infected by T2 EBV (Supplementary Figure S6). The remaining 37.2% were 
infected by multiple strains or by recombinant viruses. This approach does not allow to stratify further than the 
EBNA types.
The variant calling pipeline was adapted to output variants by minimizing the impact of the admixture ratio 
and of the low coverage observed in the SHCS samples. Variants were called against EBV-2, as EBV-2 was able 
to call more variants than EBV-1 (Supplementary Figure S7d). The benchmark experiments against AG876 
(EBV-2) yielded a total of 961 different variants. The most conservative was SNVer (783 variants), while the 
most sensitive was BCFtools 1.10.2-972 (930 variants). The variant callers can be prone to  artifacts73, which was 
specifically observed in SNVer (Supplementary Figure S7c) in these datasets. To reduce the probability of calling 
artifacts, we chose to use the bona fide intersection of GATK HC, SNVer and VarScan2. This approach is likely to 
be impacted by low coverage. The recall is stable at around 95% at 25X coverage upwards and reasonable (10%) at 
20X (Supplementary Figure S7c). Hence, low coverage has an impact, specifically, half potential variants called, 
on only 15% of the SHCS sample. However, this approach is very conservative, since it outputs only 88%, 85% 
and 79% of the variants called by SNVer, GATK HC and VarScan2, respectively.
On average, around 800 amino acid variants were called for each sample, with slight differences correlating 
with the clonality of the samples and the coverage above 6X (Supplementary Figure S7d). The variant counts 
against the AG876 construct (EBV-2) were generally higher in mixed infections and EBV-1 strains (Supple-
mentary Figure S7d A). The variant counts were generally lower in the samples included in the first sequencing 
batch, which is likely due to the fluctuating coverage. However, overall, the number of variants was found to be 
comparable across the samples, ranging from 400 to 1500 for the 77% samples with a 6X coverage above 80% 
(Supplementary Figure S7d). Under 80% coverage, the variant counts hardly exceed 500 but rarely drops under 
200 either. It is therefore likely that we missed variants using our approach. The positions covered by less than 
6 reads were considered missing and imputed afterwards using the imputePCA function implemented in the 
missMDA R-package.
We analyzed EBV variation using two approaches: single marker analysis of EBV amino acids, to investigate 
common viral variation, and burden testing of very rare amino acid variants in EBV genes (Table 1, Supplemen-
tary Figure S3). Applying logistic principal component analysis of viral genomic structure showed a single main 
cluster (Supplementary Figure S4).
Genome-to-genome association analysis. We tested for associations between each EBV variant and 
human SNPs. We studied 575 EBV amino acids and 52 EBV genes, for a total of 627 GWASs. The effective num-
ber of GWASs performed was 458. As covariates, we included the first six EBV principal components (51.4% 
deviance explained), sex, age, type 1 vs 2 of EBV (Supplementary Figure S1). The sample size ranged between 
120 and 268, with a median sample size of 264. Sample size variation was due to variable missingness in the EBV 
data. Genomic inflation factors for each of the 627 GWASs ranged between 0.92 and 1.12.
Significant associations (p < 1.09 × 10–10) were identified between a total of 25 human SNPs and viral variants 
mapping to three EBV regions (Table 2): the EBV genes BALF5 (Fig. 2A) and BBRF1 (Fig. 2B) and the EBV 
amino acid BRLF1:p.Lys316Glu (Fig. 2C). The minor allele frequency of all significant host SNPs was between 
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Strong associations were observed between 17 SNPs in the UNC5D region on chromosome 8 and the occur-
rence of very rare functional variants in the EBV BALF5 gene (Figs. 2A, 3A), which is involved in viral DNA 
replication during the late phase of lytic infection. UNC5D is a poorly characterized gene expressed mainly in 
neuronal tissues, which encodes a protein that has been shown to regulate p53-dependent apoptosis in neuro-
blastoma  cells75. The top associated SNP, rs2950922 (OR 1.31, 95% CI = 1.21–1.41, p = 4.2 × 10–12, effect allele G), 
is an eQTL for UNC5D in esophageal tissue (GTEx,71).
Rare amino acid variation in BBRF1 was found to be associated with a single SNP, rs62124869 (OR 1.29, 
95% CI 1.19–1.39, p = 4.2 × 10–11, effect allele C), which maps to the non-coding RNA gene LINC01830 (Long 
Intergenic Non-Protein Coding RNA 1830) on chromosome 2 (Figs. 2B, 3B).
Finally, 7 SNPs mapping to a non-coding region of chromosome 7 were found to be associated with the EBV 
amino acid variant BRLF1:p.Lys316Glu (Fig. 2C, 3C). The top SNP, rs6466720, had a p-value of 6.85 × 10–11 
and an OR of 1.41 (95% CI 1.28–1.58, effect allele G). BRLF1 controls lytic reactivation of EBV from latency 
and regulates viral transcription. BRLF1:p.Lys316Glu has not been described previously, but variation at the 
nearby residue 377 (BRLF1:p.Glu377Ala) has been shown to be prevalent in cases of nasopharyngeal and 
gastric carcinomas in Chinese  samples76. BRLF1:p.Lys316Glu and BRLF1:p.Glu377Ala are in moderate LD 
(r2 = 0.55) in our dataset.
Discussion
Because immunosuppression—and in particular T cell deficiency—favors EBV reactivation from its latent B cell 
reservoir, EBV viremia is frequently detected in (untreated) HIV-infected individuals with advanced disease and 
low CD4 + T cell counts. We hypothesized that the reactivated virus circulating in these patients could carry 
sequence variants acquired during primary EBV infection, thereby providing a snapshot of early adaptation to 
the pressure exerted on EBV by the individual immune response.
To search for a potential imprint of host genomic variation on the viral sequence, we jointly analyzed genomic 
information obtained from paired EBV and human samples. Viral sequence variation can be seen as an inter-
mediate phenotype, closer to potentially causal host polymorphisms than clinically observable outcomes like 
viral load or disease phenotypes. As such, it allows the detection of more subtle associations, less likely to be 
obscured by environmental influences. In our G2G analysis, we used variation at EBV amino acid residues as 
outcome in multiple parallel GWAS, which allowed us to obtain effect estimations between each human genetic 
variant and EBV variation.
We identified two EBV genes (BALF5, BBRF1) and one EBV amino acid (BRLF1 p.Lys316Glu) as associ-
ated with three regions of the human genome, spanning altogether 25 SNPs. For the GWAS with BALF5 as the 
outcome, the associated human genomic region contains eQTLs for the nearby gene UNC5D, a gene shown to 
play a role in the regulation of  apoptosis75. BALF5 encodes the DNA polymerase catalytic subunit. Localized 
within replication compartments, discrete sites in nuclei, it is one of the six proteins forming the viral replication 
complex along with processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding protein. 
It contributes to the replication of viral genomic DNA in the late phase of lytic infection, producing long con-
catemeric  DNA77. BRLF1 encodes an immediate-early transcriptional activator. It induces the initiation of viral 
lytic gene expression and lytic reactivation from latency, a key process in parrying the host immune response. 
It has also been shown to both upregulate human TNFRSF6B by directly binding to its receptor and to interacts 
with human transcription factor protein ATF7IP, potentially regulating host genes in virus-infected  cells78. EBV 
capsid assembly includes the portal oligomer, encoded by BBRF1, through which viral DNA is translocated 
during DNA packaging. Forming a homododecamer, it is translocated to the nucleus by viral scaffold protein 
Table 2.  Summary of G2G analysis results. Top SNP and/or fine-mapped SNP per locus represented with: 
EBV dataset, EBV outcome, chromosome, SNP identifier, odds ratio, p value, whether this SNP is a top SNP 
or a fine-mapped SNP, the causal probability from FINEMAP, effect allele, effect allele frequency, sample size, 
corresponding gene, variant consequence, associated eQTL gene, associated eQTL associated eQTL gene and 
p value in GTEx (from https ://gtexp ortal .org/home/)71. See Supplementary Table S1 for detailed information 
about all 25 variants and Supplementary Table S2 for fine-mapping results. *SNP with locus-wide lowest p 
value. **Odds ratio (exp(b) for logistic mixed effects model) in SHCS. ***Gene and tissue of eqtl association 
(p value of association), from GTEX: UNC5D in Esophagus_Muscularis (p = 1.15243e−13), UNC5D in 
Esophagus_Gastroesophageal_Junction (p = 2.61983e−05).
Locus EBV dataset
EBV 









variants < 1 
sample)
BALF5 rs2950922* 8 1.30739 4.2E−12 TRUE 0.13317 G 0.10821 268 UNC5D*** Intron_variant
3
Gene (binary, 
variants < 1 
sample)




1 Amino acid (binary)
BRLF1:p.
Lys316Glu rs7808072* 7 1.41346 6.8E−11 FALSE T 0.06762 244
1 Amino acid (binary)
BRLF1:p.
Lys316Glu rs6466720 7 1.42464 7.7E−11 TRUE 0.04783 G 0.06967 244
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and binds to terminase, a molecular motor, that translocates the viral DNA. The deletion of BBRF1 may be used 
in the production of DNA-free virus-like particles/light particles for preventive vaccines against hepatitis B and 
human  papillomaviruses79.
Our study is limited by its small sample size and by the complexity of correcting for human and EBV popula-
tion stratification. Indeed, if not carefully controlled for, the existence of population structure in the host and 
pathogen genome might create spurious associations or decrease real signals in G2G analyses, resulting in both 
type I and type II errors. With a mixed model approach and the inclusion of pathogen principal components as 
covariates, the genomic inflation factors of our GWAS ranged between 0.92 and 1.12. This wide range of genomic 
inflation factors is likely due to a combination of small sample size and complex statistical model. To prevent 
false positives, we adjusted for genomic inflation when extracting significant SNPs and used a conservative G2G 
Figure 2.  Significant associations—(A): BALF5, (B): BBRF1, (C): BRLF1:p.Lys316Glu. The x-axis represents the 
chromosomal position and the y-axis displays the -log10(p-value). Colour alternates between chromosomes. 
Regions that contain statistically significant SNP are presented in red (top SNP ± 400 Kbp). The light grey 
dashed line represents the GWAS significance threshold of 5 × 10–8, the dark grey dashed line the G2G threshold 
of 1.09 × 10–10. This figure was produced using  R65.
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Figure 3.  Locuszoom plots. Locuszoom plots for the three EBV association signals highlighted in red in Fig. 2 
(A: BALF5, B: BBRF1, C: BRLF1:p.Lys316Glu). This Figure was produced using  LocusZoom74.
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significance threshold of 5 × 10–8 divided by the effective number of GWAS performed. Although viral genetic 
variation is a more precise phenotype to study than traditional outcomes, it comes at the price of decreased power 
due to the high-dimensional outcome. The significance threshold is thus much lower than in a single GWAS. 
To limit the number of statistical tests performed, we restricted our analysis to common gene and amino acid 
variation.
Our analyses have been performed using historical samples collected from untreated HIV-infected individu-
als. Considering the natural history of EBV infection in humans and its high likelihood to be acquired during the 
first 2 decades of life, we postulate that intra-host adaptation of EBV happened before HIV infection, i.e. with 
a normally functioning immune system. At the time of sample collection, all study participants had advanced 
immunosuppression with low CD4 + T cell counts (< 200 cells/mm3 of blood). We therefore assume an absence 
of selective pressure on EBV at that time. These assumptions limit obviously the generalizability of our findings 
to non-HIV-infected population. Similar studies performed during primary EBV infection or in other specific 
population (e.g. bone-marrow transplant recipients) would help better delineate the global impact of intra-host 
selection on EBV sequence variation.
Our study provides a preliminary list of statistical associations between the EBV and the human genomes. 
The cataloguing of the sites of host–pathogen genomic conflict is potentially useful for further functional explo-
ration, as has been demonstrated for HIV and HCV infections. Our results require replication and validation 
in different cohorts and settings. Importantly, larger sample sizes will be needed to increase power and provide 
more robust estimations.
Data availability
The datasets generated during and/or analysed during the current study are available in the following Zenodo 
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